p53 status and gene transfer experiments using CMV enhancer/promoter

被引:6
作者
Allamane, S [1 ]
Ratel, D [1 ]
Jourdes, P [1 ]
Berger, F [1 ]
Benabid, AL [1 ]
Wion, D [1 ]
机构
[1] CHU Michallon, INSERM U318, F-38043 Grenoble 09, France
基金
澳大利亚研究理事会;
关键词
p53; gene therapy; gene transfer efficiency;
D O I
10.1006/bbrc.2000.4029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Comparison of transfection efficiencies between different commercial reagents or methods is a matter of major concern in the held of gene therapy. Transfection efficiencies are usually evaluated by the quantification of a reporter gene expression (i.e., luciferase or lacZ) whose expression is usually driven by the CMV promoter. However, this experimental approach does not consider the possible effects of the transfection on the activity of the promoter used to drive reporter genes expression. Using p53 null fibroblasts we show that transfection efficiency estimated by the use of pCMV-luc or pCMV-beta gal plasmids may be dramatically affected by the cell p53 status. These data highlight the fact that differences in p53 levels may be one of the parameters involved in the variation of transfection efficiencies observed with different cell lines. Furthermore, they point to the fact that comparison of transfection efficiencies should distinguish differences in the efficiency of transfection from differences in the level of transcription of the transgene. Finally they suggest that the known p53 down-regulation of the CMV promoter should be considered in order to avoid the nonintentional construction of transfer vectors in which the expression of a transgene down-modulates its own promoter. (C) 2001 Academic Press.
引用
收藏
页码:45 / 47
页数:3
相关论文
共 10 条
[1]
MODULATION OF CELLULAR AND VIRAL PROMOTERS BY MUTANT HUMAN P53-PROTEINS FOUND IN TUMOR-CELLS [J].
DEB, S ;
JACKSON, CT ;
SUBLER, MA ;
MARTIN, DW .
JOURNAL OF VIROLOGY, 1992, 66 (10) :6164-6170
[2]
MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[3]
WILD-TYPE P53 CAN DOWN-MODULATE THE ACTIVITY OF VARIOUS PROMOTERS [J].
GINSBERG, D ;
MECHTA, F ;
YANIV, M ;
OREN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :9979-9983
[4]
Hall PA, 1996, J PATHOL, V180, P1
[5]
JACKSON P, 1993, ONCOGENE, V8, P589
[6]
p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice [J].
Landesman-Bollag, E ;
Channavajhala, PL ;
Cardiff, RD ;
Seldin, DC .
ONCOGENE, 1998, 16 (23) :2965-2974
[7]
Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression [J].
Qin, LH ;
Ding, YZ ;
Pahud, DR ;
Chang, E ;
Imperiale, MJ ;
Bromberg, JS .
HUMAN GENE THERAPY, 1997, 8 (17) :2019-2029
[8]
RENZING J, 1995, ONCOGENE, V10, P1865
[9]
REPRESSION OF THE INTERLEUKIN-6 GENE PROMOTER BY P53 AND THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT [J].
SANTHANAM, U ;
RAY, A ;
SEHGAL, PB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (17) :7605-7609
[10]
INHIBITION OF VIRAL AND CELLULAR PROMOTERS BY HUMAN WILD-TYPE P53 [J].
SUBLER, MA ;
MARTIN, DW ;
DEB, S .
JOURNAL OF VIROLOGY, 1992, 66 (08) :4757-4762